Thermo Fisher Scientific Stock: Is Wall Street Bullish or Bearish?

Barchart
Barchart kaynağında aç
Thermo Fisher Scientific Stock: Is Wall Street Bullish or Bearish?

With a market cap of $256.1 billion, Thermo Fisher Scientific Inc. (TMO) is a global life sciences and healthcare company that provides scientific instruments, laboratory equipment, analytical technologies, reagents, consumables, and outsourced pharmaceutical services. Headquartered in Waltham, Massachusetts, the company serves pharmaceutical and biotechnology companies, hospitals, clinical laboratories, academic institutions, government agencies, and industrial customers worldwide.

Shares of Thermo Fisher have slightly lagged behind the broader market over the past year, surging 20.3% compared to the S&P 500 Index’s ($SPX) 10.7% surge. Moreover, over the past six months, the stock has soared 56.7%, also underperforming SPX’s 1.1% dip.  

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Zooming in further, the State Street Healthcare Select Sector SPDR ETF (XLV) has risen 18.7% over the past year, outperforming the stock. 

www.barchart.com

On Oct. 21, Thermo Fisher Scientific announced its third-quarter 2026 results, sending its shares up approximately 1%. The company reported a 9.1% year-over-year increase in revenue to $12.14 billion, surpassing analyst expectations of $11.95 billion, while adjusted EPS rose 15.4% to $6.68, exceeding the consensus estimate of $6.40. Organic revenue growth reached 6%, supported by strong demand across pharmaceutical services and analytical instruments. Additionally, management raised its full-year 2026 financial guidance, reflecting confidence in improving end-market demand and continued operational momentum. 

For the current year, which ends in December, analysts expect TMO’s EPS to rise 10.5% to $25.26 on a diluted basis. The company surpassed the consensus estimate in each of the last four quarters, which is impressive.      

Among the 27 analysts covering TMO stock, the consensus is a “Strong Buy.” That’s based on 20 “Strong Buy” ratings, one “Moderate Buy,” and six “Holds.”      

www.barchart.com

The configuration is bearish than a month ago, when the stock had 21 “Strong Buy” suggestions. 

On Oct. 30, Argus raised its price target on Thermo Fisher Scientific to $780 from $560 while maintaining a “Buy” rating. The firm cited the company's effective capital allocation strategy, including strategic acquisitions, facility expansions, and new AI-powered product offerings. It also highlighted Thermo Fisher's broad portfolio of reagents, antibodies, and scientific instruments, which supports drug discovery and development across the biotechnology and pharmaceutical industries.

TMO’s mean price target of $752.62 offers an upside of 8.6% compared to the current market price. Its Street-high target of $830 implies a robust 19.8% upside from current levels.      


On the date of publication, Kritika Sarmah did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Forget Apple. Warren Buffett’s Berkshire Is Pouring Nearly $1 Billion Into This Little-Known Tech Stock. DVN Short Strangle Takes Advantage of High Implied Volatility U.S. Stock Futures Rally as Anthropic Revives AI Optimism Berkshire Might Give Up on This High-Yielding Dividend Stock. You Maybe Should Too.